FluoGuide A/S (STO:FLUO)
Sweden · Delayed Price · Currency is SEK | Market Cap | 516.64M -14.2% |
| Revenue (ttm) | 404.33K -42.9% |
| Net Income | -68.52M |
| EPS | -4.45 |
| Shares Out | 16.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,758 |
| Open | 31.40 |
| Previous Close | 31.40 |
| Day's Range | 30.80 - 31.60 |
| 52-Week Range | 28.00 - 47.80 |
| Beta | 0.38 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 26, 2026 |
About FluoGuide
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the... [Read more]
Financial Performance
In 2025, FluoGuide's revenue was 220,000, a decrease of -42.86% compared to the previous year's 385,000. Losses were -39.46 million, 36.3% more than in 2024.
Financial numbers in DKK Financial StatementsNews
FluoGuide Transcript: Investing in Life Science 2026
A novel drug enabling real-time cancer visualization during surgery is advancing through clinical trials, with FDA Fast Track status for high-grade glioma and partnerships supporting market entry. Key data and new collaborations are expected within the next year.
FluoGuide Earnings Call Transcript: Q2 2026
FDA Fast Track approval and U.S. trial site opening mark key milestones, with two major clinical trials ongoing and strong focus on workflow integration. H1 net loss was DKK 24.6 million, with cash reserves at DKK 50 million. Interim results and new partnerships are expected in H2.
FluoGuide Quarterly report: Q2 2026
FluoGuide has published its Q2 2026 quarterly earnings report on August 25, 2026.
FluoGuide Earnings Call Transcript: Q1 2026
No revenues as development continues, with increased R&D spending and a net loss of DKK 11.8 million. Fast Track designation and clinical milestones drive progress, with cash runway through Q1 2027 and key trial results expected soon.
FluoGuide Quarterly report: Q1 2026
FluoGuide has published its Q1 2026 quarterly earnings report on May 27, 2026.
FluoGuide Earnings Call Transcript: Q4 2025
Three positive Phase II trials, new partnerships, and a strengthened management team marked a pivotal year, with a net loss of DKK 39 million and a strong cash position. Regulatory progress with the FDA and upcoming clinical milestones set the stage for further growth.
FluoGuide Annual report: Q4 2025
FluoGuide has published its Q4 2025 annual report on February 25, 2026.
FluoGuide Quarterly report: Q4 2025
FluoGuide has published its Q4 2025 quarterly earnings report on February 25, 2026.
FluoGuide Slides: SEB Nordic Seminar presentation
FluoGuide has posted slides in relation to its latest quarterly earnings report, which was published on January 7, 2026.
FluoGuide Quarterly report: Q3 2025
FluoGuide has published its Q3 2025 quarterly earnings report on November 27, 2025.